Payment & Shipping Terms:
NM-2201 (also known as CBL-2201) is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB1 and CB2 receptors with low nanomolar affinity.
NM-2201 acts as a full agonist with a binding affinity of 0.332nM at CB1 and 0.732nM at CB2 cannabinoid receptors.
It is a drug that presumably acts as a potent agonist for the cannabinoid receptors. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in July 2012 as an ingredient in synthetic cannabis smoking blends Like the closely related NM-2201 which had been first reported around a year earlier,
NM-2201 thus appears to be another novel compound invented by designer drug suppliers specifically for recreational use.
Structurally, NM-2201 is a hybrid of two known cannabinoid compounds JWH-210 and NM-2201, both of which had previously been used as active ingredients in synthetic cannabis blends before being banned in many countries.